BioXcel Therapeutics Shares Rally 17.6% After BXCL501 Cuts Withdrawal By Over 30%
BioXcel Therapeutics reported that its Phase 2 trial of BXCL501 at 240 µg twice daily yielded more than 30% reduction in opioid withdrawal symptoms on days 3-4, numerically surpassing lofexidine’s efficacy with fewer cardiovascular effects. Shares jumped 17.6% during premarket trading on the news.
1. Phase 2 Trial Results
BioXcel Therapeutics achieved topline success in its Phase 2 study of BXCL501 for opioid withdrawal, where a 240 µg twice-daily dose produced over 30% reduction in Short Opiate Withdrawal Scale–Gossop scores. Peak symptom relief occurred on days 3 and 4, and BXCL501’s efficacy numerically exceeded lofexidine 0.54 mg administered four times daily while exhibiting fewer cardiovascular side effects.
2. Stock Reaction
Following announcement of the positive topline data, BioXcel shares climbed 17.6% to $1.94 during premarket trading, trading 1.5% above their 20-day moving average but remaining 5.2% below the 100-day average. Technical indicators showed a neutral RSI at 50.00 and a bearish MACD at 0.10 versus a 0.15 signal line, signaling mixed momentum despite the rally.
3. Pipeline Implications
The robust performance of BXCL501 in opioid withdrawal underscores its status as a “pipeline within a product,” with ongoing development in acute agitation for bipolar disorder and schizophrenia. Earlier in September 2025, a pivotal at-home Phase 3 safety trial demonstrated consistent benefit with repeat dosing, reinforcing the drug’s broader therapeutic potential.